Double attack on tough myeloma: stem cell transplant plus CAR-T cells
NCT ID NCT05632380
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 31 times
Summary
This study combines a stem cell transplant with a special immune cell therapy (C-CAR088) to treat people with ultra high-risk multiple myeloma, a blood cancer that is hard to treat. The 20 participants will receive their own stem cells after high-dose chemotherapy, followed by a single infusion of CAR-T cells that target the BCMA protein on myeloma cells. The goal is to see if this powerful combination is safe and can control the disease better than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
C-CAR088 (a CAR-T cell therapy targeting BCMA) and autologous hematopoietic stem cell transplant
What this could lead to
If successful, this combination could offer a more effective treatment option for patients with ultra high-risk multiple myeloma who have limited alternatives.
What could go wrong
This is an early-phase trial with only 20 participants, so results may not apply broadly. There are risks of serious side effects from both the transplant and CAR-T therapy, and the treatment may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.